Role of ulinastatin in pancreatitis

Role of ulinastatin in severe acute pancreatitis - a randomized controlled study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/07/020313

Enrollment

Registered

2019-07-22

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K859- Acute pancreatitis, unspecified

Interventions

Intervention1: Ulinastatin: Ulinastatin in the dose of 100,000 IU in 100 ml normal saline TDS for 7 days Control Intervention1: Placebo: 100 mL normal saline TDS for 7 days

Eligibility

Inclusion criteria

Inclusion criteria: Patients aged 18 - 80 years with severe acute pancreatitis presenting to Lok Nayak Hospital

Exclusion criteria

Exclusion criteria: 1. Mild pancreatitis 2. Pregnancy 3. Lactation 4. Allergy to ulinastatin 5. Chronic pancreatitis 6. Traumatic pancreatitis

Design outcomes

Primary

Measure	Time frame
1. Mortality Timepoint: 1 week, 2 weeks, 1 month and 3 months	—

Secondary

Measure	Time frame
Local and systemic complications Duration of stay in hospital Need for surgical interventionTimepoint: 1 week, 2 weeks, 1 month and 3 months	—

Countries

India

Contacts

Public ContactAdiba Nizam

Maulana Azad Medical College

sudhirkumar11@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026